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Abstract
Background: Rotavirus is the most common cause of severe diarrhea in Nepali children, 
accounting for 25%−33% of childhood diarrhea hospitalizations. Two rotavirus vaccines 
recommended for inclusion in national immunization programs have been associated with a low 
risk of intussusception in post-marketing studies conducted in several countries. Data on the 
epidemiology of intussusception hospitalizations are lacking in Nepal. Thus, we aimed to describe 
the epidemiology of intussusception-associated hospitalizations among Nepali children in 
preparation for rotavirus vaccine introduction.
Methods: A retrospective review of intussusception hospitalizations for a three year period was 
conducted at two major pediatric hospitals in Kathmandu, Nepal. Possible intussusception cases 
were identified through admission, discharge, and operation theater logs and ultrasound registers. 
Cases with a diagnosis of possible intussusception were selected for medical record review and 
classified as confirmed if they met the Brighton Collaboration level 1 criteria of diagnostic 
certainty and the child was aged <24 months. Data on demographics, clinical course, and outcome 
were abstracted and analyzed.
Results: Eight-five confirmed intussusception cases were identified; most (96%) were confirmed 
at surgery. The number of intussusception cases peaked between ages 4–7 months; no cases 
occurred in children 0–2 months. Fifty-nine (64%) case-patients were male. The median duration 
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of symptoms before admission was 2 days (range: 0–14). Abdominal pain, bloody stool, and 
vomiting were the most common clinical features. All cases underwent surgical treatment; there 
was only one death.
Conclusions: This is the first study to evaluate the epidemiology of intussusception 
hospitalizations among children aged <24 months in Nepal. Because the public health impact of 
rotavirus vaccination could be substantial in Nepal, where childhood diarrhea-related morbidity 
and mortality are high, this baseline knowledge of intussusception prior to introduction of 
rotavirus vaccine in the national immunization schedule will provide useful information for post-
vaccine introduction safety monitoring.
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INTRODUCTION
Diarrhea is the second most common cause of death in Nepali children [1], and rotavirus is 
the most common cause of severe diarrhea in these children, accounting for 25%−33% of 
childhood diarrhea hospitalizations [2, 3]. Because of this substantial burden of disease, the 
Government of Nepal has included rotavirus vaccine on its priority list for new vaccines and 
plans to include rotavirus vaccine in the national immunization programme in the near 
future.
In 1999, a first generation oral rotavirus vaccine, Rotashield (Wyeth-Lederle), was 
withdrawn from the US market because of an increased risk of intussusception, estimated at 
one excess case occurring among every 10,000 vaccinated children, primarily in the first 
week after the first vaccine dose [4, 5]. The two currently licensed oral rotavirus vaccines, 
Rotarix (GlaxoSmithKline Biologicals, Rixensart, Belgium) and RotaTeq (RotaTeq, Merck 
and Co., Whitehouse Station, New Jersey), were assessed for intussusception in large pre-
licensure clinical trials [6, 7]. While no increased intussusception risk was observed in these 
trials, post-marketing studies in several upper middle to high income countries have detected 
a small increased risk of intussusception associated with both vaccines, with an estimated 1 
to 5 excess cases per 100,000 vaccinated children [8–13]. Therefore, the World Health 
Organization recommends monitoring for intussusception in countries implementing 
rotavirus vaccines [14].
Intussusception is a rare condition in which the invagination of one segment of the bowel 
into another distal segment can result in obstruction, vascular compromise, necrosis of the 
intestine, perforation and even death if untreated. It is the most common cause of acute 
bowel obstruction in children below two years of age, with an estimated mean global 
incidence of 74 cases (range: 9–328) per 100,000 children aged <1 year [15]. However, the 
incidence of intussusception varies substantially by geographic region and limited data on 
intussusception are available from low income countries of Asia and Africa. Genetic 
predisposition, circulating pathogens, differences in feeding practices and environments, and 
differences in access to health care and diagnostic practices could also contribute to the 
global differences in intussusception rates [15].
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Data on the epidemiology of intussusception-associated hospitalizations are currently 
lacking in Nepal. Hence, we examined the immediate clinical outcomes and described the 
epidemiology of intussusception-associated hospitalizations among children in Nepal in 
preparation for rotavirus vaccine introduction.
METHODS
We conducted a retrospective review of intussusception hospitalizations for a three year 
period from 1 July 2011 through 30 June 2014 at Kanti Children’s Hospital (KCH), 
Maharajgunj and Ishan Children and Women’s Hospital Pvt Ltd (ICWH), Basundhara, two 
major pediatric hospitals in Kathmandu, Nepal. These two sites were selected as they receive 
the majority of pediatric surgical case referrals and manage the majority of pediatric 
intussusception cases in Nepal. KCH is a public facility providing heavily subsidized to 
almost free care to residents of Nepal, while ICWH is a private facility where patients pay 
for services.
A member of the research team identified possible intussusception cases through review of 
hospital admission, discharge and operation theater logs and ultrasound registers. Any case 
with a diagnosis of intussusception was selected for medical record retrieval and case 
inclusion screening. Children with suspected intussusception were classified as having a 
confirmed case of intussusception if they met the following inclusion criteria: 1) age <24 
months and 2) criteria meeting the Brighton Collaboration level 1 of diagnostic certainty. 
Cases met Brighton level 1 diagnostic criteria if they had any of the following findings: a) 
invagination of the intestine at surgery, b) demonstration of invagination of the intestine by 
either air or liquid contrast enema or demonstration of an intra-abdominal mass by 
abdominal ultrasound with specific characteristic features (target sign or doughnut sign on 
transverse section and a pseudokidney or sandwich sign on longitudinal section), that was 
proven to be reduced by hydrostatic enema on post-reduction ultrasound, and/or c) 
demonstration of invagination of the intestine at autopsy [16].
Medical records of all children with a confirmed diagnosis of intussusception were 
reviewed, and data on demographics, clinical illness course, and diagnostic, treatment and 
outcome information were abstracted using a standardized questionnaire. Descriptive 
epidemiological analyses were conducted using SPSS version 16 and SAS version 9.3.
This study was approved by the ethical committee of the Nepal Health Research Council, 
Ethical review board of Kanti Children’s Hospital.
RESULTS
Overall, we identified 106 possible cases of intussusception in children age <24 months 
admitted to KCH and ICWH during the 3-year study period. Of the 106 cases, three (3%) 
had their specific age missing and 18 (17%) did not meet the Brighton Collaboration level 1 
diagnostic criteria, so these cases were excluded. A total of 85 cases (74 [87%] from KCH 
and 11 [13%] from ICWH) were included in the analysis (Figure 1); over half (68%) were 
children from the Central Development Region of Nepal (Table). Eighty-two cases (96%) 
were confirmed at surgery.
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Of the 85 confirmed intussusception cases, the number of cases peaked between the ages of 
4 and 7 months (Figure 2), with a median age of 7 months (range: 3–23). No cases occurred 
in children aged 0–2 months, and there was no apparent seasonal pattern in case occurrence 
(Figure 3). Fifty-nine (64%) case-patients were male; the male: female ratio of cases-
patients was 2.3:1 (Table). The median duration of symptoms before admission was 2 days 
(range: 0–14). Abdominal pain (64%), bloody stool (60%), and vomiting (59%) were the 
most common clinical features reported. The most common type of intussusception was 
ileocolic (72%). All cases underwent surgical treatment – 73% underwent surgery with 
simple manual reduction of the intussusception and were discharged home without 
complications, while 27% required intestinal resection. There was only one death. For 72 
cases with available admission and discharge date data, the median length of hospital stay 
was 6 days.
DISCUSSION
This study provides baseline epidemiological information on naturally occurring 
intussusception among children aged <24 months in Nepal. Important to note is the lack of 
cases that occurred during the first 3 months of life and the low mortality rate, despite the 
fact that all cases underwent surgical intervention. Our findings are consistent with other 
reports from the United Kingdom, Republic of Ireland, Australia, and Malaysia that have 
described the peak age of intussusception incidence occurring in the first year of life, with a 
very low incidence in the first 2–3 months of life [17–19]. Also consistent is the male 
predominance of cases [20–22]. This male predominance is not completely understood, but 
could suggest genetic predisposition to having intussusception and/or differences in access 
to health care. Although all intussusception cases underwent surgical intervention, the time 
between onset of symptoms and hospital admission was very short, likely resulting in the 
good outcomes seen in most cases. The probable reasons for the preference of surgical 
intervention are that, in Nepal, there is greater surgical experience in treating 
intussusception, and hydrostatic reduction is not common. Radiologists are not trained in 
hydrostatic intussusception reduction, and the pediatric surgeons who would be trained in 
hydrostatic reduction techniques are more experienced with surgical reduction.
This study had several limitations. First, this study may not be nationally representative of 
all intussusception cases in Nepali children <24 months of age as more than half of the 
intussusception cases were from the Central Development Region where the two hospitals 
are located. However, the distribution of cases from almost all the regions of Nepal and our 
informal survey of referral patterns for pediatric intussusception for which we found that 
almost all cases are referred to Central Development Region hospitals provide support that 
our findings could be representative of the whole country. Second, recruitment of cases 
depended on retrospective review of the diagnosis of intussusception recorded on medical 
charts and other logs. Hence, those without clear documentation of diagnosis may have been 
missed. Additionally, some intussusception cases treated by general surgeons in other 
hospitals may have been missed. This selection bias could result in an underestimation of the 
total number of intussusception cases. Also, more recent cases may be more likely to be 
identified than cases which occurred earlier in the study period due to improved record 
keeping and record availability over time. Finally, rotavirus vaccines are available on the 
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private market in Nepal however we were unable to reliably assess the vaccination status of 
enrolled cases due to the retrospective study design.
In conclusion, this is the first study to evaluate the epidemiology of intussusception 
hospitalizations among children aged <24 months in Nepal. Because the public health 
impact of rotavirus vaccination could be substantial in settings like Nepal, where childhood 
diarrhea-related morbidity and mortality are high, this baseline knowledge of 
intussusception prior to introduction of rotavirus vaccine in the national immunization 
schedule will provide useful information for post-vaccine introduction safety monitoring.
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Figure 1. 
Flow chart of children <24 months of age admitted to KCH and ICWH with a diagnosis of 
intussusception − 1 July 2011 through 30 June 2014
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Figure 2. 
Intussusception hospitalizations among children below 2 years of age at KCH and ICWH, by 
age in months – 1 July 2011 through 30 June 2014 (N=85)
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Figure 3. 
Intussusception hospitalizations among children below 2 years of age at KCH and ICWH, by 
month and year – 1 July 2011 through 30 June 2014 (N=85)
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Table.
Characteristics and clinical course of intussusception case-patients <2 years of age admitted to KCH and 
ICWH, July 2011–June 2014
Characteristics and clinical course Intussusception case-patients (N=85)
Median (range) age in months 7 (3–23)
Sex
 Male 59 (64%)
 Female 26 (28%)
Region of residence
 Central 51 (68%)
 Eastern 14 (19%)
 Western 9 (12%)
 Mid-western 1 (1%)
 Unknown 10 (12%)
Median (range) days from symptom onset to hospital admission 2 (0–14)
Mode of diagnosis
 Surgery 82 (96%)
 Ultrasound 3 (4%)
Presence of signs and symptoms
 Abdominal pain 54 (64%)
 Bloody stools 51 (60%)
 Vomiting 50 (59%)
 Fever 17 (20%)
 Diarrhea 10 (12%)
 Constipation 3 (4%)
Location of intussusception
 Ileocolic 61 (72%)
 Compound 11 (13%)
 Unknown 9 (11%)
 Ileoileal 4 (5%)
 Colocolic 0 (0%)
Intussusception management
 Surgery without intestinal resection 62 (73%)
 Surgery with intestinal resection 23 (27%)
Post-management complications
 No known complications 77 (91%)
 Peritonitis 2 (2%)
 Wound dehiscence and intestinal obstruction 2 (2%)
 Secondary intestinal obstruction 2 (2%)
 Wound dehiscence 1 (1%)
 Wound infection 1 (1%)
Outcome
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Characteristics and clinical course Intussusception case-patients (N=85)
 Survived and discharged home 79 (93%)
 Unknown 5 (6%)
 Died 1 (1%)
 Transferred to another health facility 0 (0%)
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